ArticleDiscover oncology2025
Meningeal malignant solitary fibrous tumor with multiple recurrence, extracranial extension, cervical lymph node metastases: case report and review of the literature.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSolitary fibrous tumor (SFT) of the central nervous system (CNS) is a spindle cell neoplasm originating from mesenchymal tissue. SFT is prone to local recurrence or distant metastasis. The main sites of metastasis include the liver, lung, and bone. However, the tumor direct extracranial extension via natural skull base foramina to cervical region is rare. CASE PRESENTATION: A 43-year-old male presented with an incidentally discovered left temporo-occipital region mass spanning the tentorium cerebelli identified during head and neck CT angiography, initially suspected as meningioma. The patient underwent gross total resection, with histopathological confirmation of a grade III malignant solitary fibrous tumor (WHO CNS 2007) originating from the left tentorium cerebelli. Immunohistochemical analysis demonstrated tumor cell positivity for CD34, vimentin, and Ki-67 (approximately 10%), while negative for EMA, PR, and P53. Subsequent disease progression manifested as multiple local recurrences with sacral and left pubic metastases. Multimodal management included adjuvant radiotherapy-Intensity-modulated radiation therapy (IMRT) and Gamma Knife radiosurgery(GKRS)-and concurrent bone-modifying agents (Ibandronate Sodium) for skeletal metastases. In June 2020 re-evaluation prompted by a palpable left neck mass revealed magnetic resonance imaging (MRI)-documented multifocal recurrence involving the left mastoid process and tentorium cerebelli, with extended through the jugular foramen into the left parapharyngeal space and involved the left cervical lymph nodes IMRT was performed with a prescribed dose of 54 Gy in 30 fractions. After completion of the treatment course, significant regression of most lesions was observed. However, the patient discontinued clinical follow-up after July 2021. Subsequent telephone contact confirmed expiration in September 2022 secondary to disease progression.
conclusionsWe report the first case of extracranial extension and cervical lymph node metastases from meningeal malignant SFT. This finding provides novel insights into the dissemination patterns of intracranial SFT. Surgical resection is the gold standard for the treatment. Postoperative radiotherapy (PORT) whether gross total resection (GTR) or subtotal resection (STR) may be the optimal treatment strategy, but PORT dose < 60 Gy with IMRT or marginal dose < 15 Gy with GKRS may be insufficient. Close and long-term follow-up, especially in the first five years after diagnosis, is essential to manage such patients because of high risk of recurrence and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.